Abstracts Archive - Page 1628 of 2607 - ACR Meeting Abstracts

Abstract Number: 425 • 2016 ACR/ARHP Annual Meeting
Improving Pneumococcal Vaccination Rates for Immunosuppressed Patients in an Academic Rheumatology Clinic
Alison Bays¹, Renuka R. Nayak², Sara Murray³, Darlene Young⁴, Gabriela Schmajuk⁵, Jinoos Yazdany⁶ and Andrew Gross⁷, ¹Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, UCSF, San Francisco, CA, ³Medicine, UCSF, San Francisco, CA, ⁴Medicine/Rheumatology, UCSF, San Francisco, CA, ⁵San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Patients with autoimmune conditions have higher rates of pneumococcal disease and they are often immunosuppressed. In 2014, the Advisory Committee on Immunization Practices issued…
Abstract Number: 426 • 2016 ACR/ARHP Annual Meeting
Herpes Zoster Vaccine: A Quality Improvement Study in Rheumatoid Arthritis Patients
Rochella A. Ostrowski and Hina Chaudhry, Rheumatology, Loyola University Medical Center, Maywood, IL
Herpes Zoster Vaccine: A Quality Improvement Study in Rheumatoid Arthritis Patients Chaudhry, Hina S.; Ostrowski, Rochella A. Division of Allergy, Immunology, and Rheumatology, Loyola University…
Abstract Number: 427 • 2016 ACR/ARHP Annual Meeting
Identifying Barriers to Zoster Vaccination Rates Among RA Patients in an Academic Rheumatology Practice
Ami Joglekar¹, Ashley Blaske² and Narender Annapureddy³, ¹Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, ²Internal Medicine/Pediatrics, Vanderbilt University, Nashville, TN, ³Vanderbilt University, Nashville, TN
Background/Purpose: The risk of herpes zoster (HZ) infection in patients with rheumatic disease is 1.5 to 2 times that of the general population. The 2012 ACR Treatment…
Abstract Number: 428 • 2016 ACR/ARHP Annual Meeting
Random Forest Models Using Electronic Health Record Data Are Predictive of One-Year Outcomes in Lupus Nephritis Patients Taking Mycophenolate Mofetil Induction Therapy
Bethany J Wolf¹ and Jim Oates^2,3, ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medical Service, Rheumatology Section, Ralph H. Johnson VAMC, Charleston, SC, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) outcomes are affected not only by patient biology but also by patient, provider, and system factors. One way to improve outcomes…
Abstract Number: 429 • 2016 ACR/ARHP Annual Meeting
Use of Electronic Medical Record to Identify Immunocompromised Patients in a Pediatric Rheumatology Clinic
Leslie A. Favier¹, Emily A. Smitherman¹, Adam Furnier², Tracy Ting³, Allen Watts¹, Sandra Kramer⁴, Mitesh Parwani⁴ and Jennifer L. Huggins¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology/MLC 4010, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The increase in therapeutic options for our Pediatric Rheumatology patients has led to improved outcomes but has increased the number of immunocompromised (IC) patients. …
Abstract Number: 430 • 2016 ACR/ARHP Annual Meeting
A Process to Obtain Hepatitis B Serology Screening on Immunocompromised Pediatric Rheumatology Patients
Emily Smitherman¹, Leslie A. Favier¹, Adam Furnier², Sandra Kramer³, Barbara Speer⁴, John Kues⁴, Lara Danziger-Isakov³, Rebecca Brady⁵ and Jennifer L. Huggins⁶, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴University of Cincinnati, Cincinnati, OH, ⁵Division of infectious diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: In the setting of today’s heroin epidemic, hepatitis B infection remains a significant public health concern, especially for patients with immunocompromising conditions. With reports…
Abstract Number: 431 • 2016 ACR/ARHP Annual Meeting
Wide Variations in Hepatitis B Screening Practices for Patients Receiving Rituximab
Gabriela Schmajuk¹, Chris Tonner², Laura Trupin³, Jing Li⁴ and Jinoos Yazdany³, ¹San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Hepatitis B reactivation in the setting of rituximab use is a potentially fatal but preventable event. The rate of hepatitis B screening in patients…
Abstract Number: 432 • 2016 ACR/ARHP Annual Meeting
Monitoring Hepatitis B Screening Compliance in Patients with Rheumatoid Arthritis (RA) Receiving Anti-TNF Therapy
Vedashree Panthulu¹ and John Waterman², ¹Rheumatology, University of Connecticut Health Center, Farmington, CT, ²Rheumatology, Connecticut VA Healthcare System, Newington, CT
Background/Purpose: The risk of infection in patients with RA is higher than in comparable patients but still the vaccination rates in RA patients are low. …
Abstract Number: 433 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Latent Tuberculosis and Hepatitis B Found after Systematic Screening of Patients Starting with Biological Therapy in a Low-Endemic Area
Marin de Jong^1,2, Danielle Roosen¹, Andy Peters¹, Valerie Verstraeten³, Marieke Pierik¹ and A. van Tubergen⁴, ¹Department of Internal Medicine, division of Gastroenterology, Maastricht University Medical Centre, Maastricht, Netherlands, ²NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, Netherlands, ³Department of Dermatology, Maastricht University Medical Centre, Maastricht, Netherlands, ⁴Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Biologicals are a powerful treatment option for moderate to severe immune-mediated inflammatory diseases (IMID). Since biologicals modulate the immune system, the risk for reactivation…
Abstract Number: 434 • 2016 ACR/ARHP Annual Meeting
Nurse Scheduled Telephone Visit: The Right Rheumatology Care for the Right Patient at the Right Time
Shazdeh Butt¹, Eric Newman² and Natasha Smith¹, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Department of Rheumatology, Geisinger Medical Center, Danville, PA
Background/Purpose: Rising healthcare costs have resulted in greater patient burden, higher health insurance costs, deductibles, and copayments. Access to care is delayed and problematic. Many…
Abstract Number: 435 • 2016 ACR/ARHP Annual Meeting
It Takes Two, an Interdisciplinary Approach to Increasing Hydroxychloroquine Screening Adherence
Christina Downey¹, Tombra Govina¹ and Eric Newman², ¹Geisinger Medical Center, Danville, PA, ²Department of Rheumatology, Geisinger Medical Center, Danville, PA
Background/Purpose: Hydroxychloroquine (HCQ) is a widely used rheumatologic drug that carries a risk for irreversible retinal toxicity. The incidence of adverse effect increases to greater…
Abstract Number: 436 • 2016 ACR/ARHP Annual Meeting
Are Providers Recommending Appropriate Screening for Hydroxychloroquine-Induced Retinal Toxicity to Their Patients?
Sarah Haserodt¹, Chris Tonner², Gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Internal Medicine, California Pacific Medical Center, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Although well tolerated by most patients, hydroxychloroquine (HCQ) can cause irreversible retinal damage. The American Association of Ophthalmology (AAO) 2016 Guidelines recommend a baseline…
Abstract Number: 437 • 2016 ACR/ARHP Annual Meeting
Incidence of Gastrointestinal Events and Physician Compliance of Co-Prescribing Proton Pump Inhibitors in Chronic NSAID Users with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis
Arina Garg, Rakeeba Din, Daniel Torres Leyva, Maryam Hasan, Ma Moe and Bruce Garner, NYU Lutheran Medical Center, Brooklyn, NY
Background/Purpose: The most common group of patients with chronic use of NSAIDs include those with rheumatic diseases such as osteoarthritis (OA), rheumatoid arthritis (RA) and…
Abstract Number: 438 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Adverse Effects – the Patient Perspective
Rachel Black¹, Susan M. Goodman², Carlee Ruediger³, Susan Lester⁴, Sarah Mackie⁵ and Catherine Hill³, ¹Department of Medicine, The University of Adelaide, Adelaide, Australia, ²Medicine, Hospital for Special Surgery, New York, NY, ³Medicine, The University of Adelaide, Adelaide, Australia, ⁴Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom
Background/Purpose: Glucocorticoid (GC) use and adverse effects (AEs) are prevalent in rheumatic diseases, yet there is no standardized patient-reported outcome measure to assess benefit and…
Abstract Number: 439 • 2016 ACR/ARHP Annual Meeting
Temple University Hospital Rheumatology Narcotic Contract
Alexis Zavitsanos¹, King Goh², Shikha Rathi³, Alice Livshits³ and Irene Tan³, ¹Rheumatology, Temple University Hospital, Philadelphia, PA, ²Rheumatology, Temple University, Philadelphia, PA, ³Temple University Hospital, Philadelphia, PA
Background/Purpose: The use of opioids in treating chronic pain can be difficult and is a common problem across multiple specialties, including rheumatology. Opioid contracts have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].